Frontiers in strokeSep 9, 2026

Using SGLT2 inhibitors and incretin-based drugs for heart and metabolism health after stroke

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 10, 2026

Abstract

Two novel drug classes, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, may improve long-term outcomes for stroke patients.

Cardiovascular risk factors and comorbidities are common in individuals experiencing acute stroke.
Current secondary stroke prevention guidelines do not include these new drug classes.
Emerging evidence suggests these medications could enhance management of cardiovascular conditions related to stroke.
Staying informed about these developments is critical for optimizing treatment and reducing future risks.

Simplified

Stroke is a multifactorial cardiovascular disease (CVD), which predominantly affects older adults. Consequently, cardiovascular risk factors and related comorbidities are highly prevalent among people presenting with acute stroke. These conditions, and the stroke event itself, may require specific pharmacological therapies to reduce subsequent risk. Over recent decades, two novel pharmacological drug classes, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, which were initially developed as glucose-lowering therapies for type 2 diabetes mellitus, have been used for management of related cardiovascular conditions. These agents are not currently included in secondary stroke prevention guidelines, despite growing evidence suggesting that they may directly or indirectly improve long-term, stroke-related outcomes. It is therefore essential that the stroke community remains up-to-date with these developments while awaiting updated clinical guidelines. This will ensure optimal management of coexisting cardiovascular disease and reduce subsequent risk. In this commentary, we summarize and discuss what we consider to be the most relevant and impactful recent studies for contemporary clinical stroke practice.

Full Text

Full text is available at the source.

View Full Text ↗

Using SGLT2 inhibitors and incretin-based drugs for heart and metabolism health after stroke

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief